65,437 trials
Tenosynovial Giant Cell Tumor · Pigmented Villonodular Synovitis (PVNS)
Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 2 Participants
Opioid-use Disorder · Opioid Use · Opioid Abuse
Primary: Frequency of PDMP Checks — 19; 23; 31.9; 22.1 PDMP queries per PCP per month
Pediatric Central Nervous System Tumor
Primary: Sensitivity and Specificity of Tozuleristide Fluorescence to Detect Tumor in Equivocal (Ambiguous) Tissue During Surgery When Imaged With the Canvas System — 79.8; 34.7…
Bladder Cancer · Bladder Tumor · Muscle-Invasive Bladder Cancer
Primary: Pathologic Complete Response (pCR) Rate- Nivolumab + Bempegaldesleukin Compared to Standard of Care — 10.8; 2.5 Percentage of participants
Cannabis Use
Primary: Global Cognitive Ability (GCA) — -1.99; -0.82 Standard score (Z-score) — p=0.005
Healthy · Chronic Illnesses, Multiple
Primary: Change From Baseline in Adolescents' Knowledge About Clinical Trials at Week 1 — 40.32; 40.33 units on a scale — p=.99
Neoplasms
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Daily Oral Lisavanbulin — 16; 30 mg
Sickle Cell Disease
Primary: Mean Change in Biomarker Fetal Hemoglobin (HbF) — 2.7; 0.3; -1.7; 1.8 Percent fetal hemoglobin — p=0.067
Human Immunodeficiency Virus
Primary: Report of HIV Self-test Result — 59; 63; 688; 668 Participants
Posttraumatic Headache · Combat Disorders · Post Concussion Syndrome
Primary: Headache Diary — -10.7; -6.9 headaches per month — p=0.034
Naloxone
Primary: Change in Naloxone Dispensing Rate Over a 6-month Period — .0073; .0041 number of naloxone products dispensed — p=0.473
Bipolar Disorder · Bipolar I Disorder · Bipolar II Disorder
Primary: Change in dACC GSH Levels Through Proton Magnetic Resonance Spectroscopy — 2.426; 2.207 Institutional Units
Breast Surgery
Primary: Recovery Room Numeric Rating Scale Pain Scores — 3.3; 1.3 score on a scale
COVID-19 · Viral Respiratory Illnesses
Primary: The Proportion of Subjects With Symptomatic Laboratory-confirmed COVID-19 Identified After Start of Treatment and Before the End of the 6-week Treatment Period. — 0.02…
Alopecia Areata
Primary: Percent Change From Baseline in Severity of Alopecia Tool I (SALT I) at Week 24: DB Treatment Period — -13.79; -21.43; 0.35 Percent change of scalp surface area — p=0.2579